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ABSTRACT
Toxic gain-of-function mutations in aminoacyl-tRNA
synthetases cause a degeneration of peripheral mo-
tor and sensory axons, known as Charcot–Marie–
Tooth (CMT) disease. While these mutations do not
disrupt overall aminoacylation activity, they inter-
fere with translation via an unknown mechanism.
Here, we dissect the mechanism of function of CMT
mutant glycyl-tRNA synthetase (CMT-GARS), using
high-resolution ribosome profiling and reporter as-
says. We find that CMT-GARS mutants deplete the
pool of glycyl-tRNAGly available for translation and
inhibit the first stage of elongation, the accommoda-
tion of glycyl-tRNA into the ribosomal A-site, which
causes ribosomes to pause at glycine codons. More-
over, ribosome pausing activates a secondary re-
pression mechanism at the level of translation ini-
tiation, by inducing the phosphorylation of the alpha
subunit of eIF2 and the integrated stress response.
Thus, CMT-GARS mutant triggers translational re-
pression via two interconnected mechanisms, affect-
ing both elongation and initiation of translation.
INTRODUCTION
Defects in translational regulation have been identified as
common features in multiple neurodegenerative disorders
(reviewed in (1)). Yet in some cases the precise mechanisms
by which they disrupt translation have to be clarified. For
protein synthesis, amino acids are ligated to their cognate
tRNAs by aminoacyl-tRNA synthetases (aaRSs), and mu-
tations in six of these enzymes cause a degeneration of
peripheral motor and sensory axons, known as Charcot–
Marie–Tooth (CMT) disease (reviewed in (2)). A subtype
of this disease, CMT type 2D (CMT2D), is caused by dom-
inant mutations in the gene encoding glycyl-tRNA syn-
thetase (GARS). Curiously, although overall aminoacyla-
tion activity is not disrupted by CMT2D-causing muta-
tions, global translation is inhibited (3–7). This raises the
question about the mechanisms of translational repression
in this disease.
Translation cycles through three stages: initiation, elon-
gation and termination. Because initiation is the rate-
limiting stage of translation, it has been considered the
main stage at which translational control occurs (reviewed
in (8)). Eukaryotic translational initiation is a multi-step
process that requires many proteins, the so called eukary-
otic initiation factors (eIFs). It involves the formation of
the 43S pre-initiation complex, which consists of the small
(40S) ribosomal subunit, ternary complex (the initiator
Met-tRNAi and eIF2 in its GTP-bound form, hereafter re-
ferred to as eIF2:GTP:Met-tRNAi), and other factors. The
43S complex is recruited to the mRNA 5′-end and scans
the mRNA until it finds the initiation AUG codon and
can bind the large (60S) ribosomal subunit. Joining of the
large (60S) ribosomal subunit completes formation of the
80S ribosome with aminoacylated tRNA in the ribosomal
P-site.
Most of the steps of initiation can be regulated. A major
regulatory mechanism is triggered by various stress condi-
tions and is called the integrated stress response (ISR, re-
viewed in (9)). It involves the phosphorylation of the al-
pha subunit of eIF2 (eIF2a), which reduces the levels of
the ternary complex eIF2:GTP:Met-tRNAi. This leads to a
downregulation of global translation initiation, to save cel-
lular resources under stress conditions, and the upregula-
tion of specific transcripts, such as Activating transcription
factor 4 (ATF4), required to fix stress-related damage (10–
12). A number of reports have found that ISR is activated
in neurodegenerative diseases, including Alzheimer’s and
prion disorders (13), amyotrophic lateral sclerosis (14) and
cerebellar and retinal degeneration (15).
Recent evidence has shown that the stage of elongation
of translation can also be targeted by complex regulatory
mechanisms, and that this plays important roles in devel-
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opment and neurologic diseases (reviewed in (16)). Muta-
tion in the ribosome rescue factor GTPBP2, underlying
cerebellar and retinal degeneration (17), has been associ-
ated with ribosome stalling during elongation (15). Simi-
lar effects have been reported for FMRP-linked disorders,
Fragile X syndrome and autism (18). Elongation requires
two eukaryotic elongation factors (eEFs) and consists of
three main steps: (i) the accommodation of the aminoacy-
lated tRNA (aa-tRNA), in complex with eEF1A:GTP, into
the A-site of the ribosome, (ii) the formation of the pep-
tide bond, catalyzed by the large ribosomal subunit, during
which the growing polypeptide from the P-site is transferred
to aa-tRNA in the A-site, (iii) ribosome translocation, cat-
alyzed by eEF2, during which peptidyl-tRNA moves to the
P-site and deacylated tRNA is evicted from the P-site. Ribo-
somes undergo major conformational rearrangements dur-
ing elongation, and recent works have shown that ribosome
profiling can distinguish between two functional states of
the ribosome––before and after aa-tRNA binding (19,20).
Here, we dissect the mechanism of translational reg-
ulation by CMT2D-causing mutations in GARS (CMT-
GARS). Using high-resolution ribosome profiling, we show
that CMT-GARS mutant G240R causes ribosomes to stall
at glycine codons in open A-sites, due to increased retain-
ment of tRNAGly on mutant CMT-GARS and a shortage
of glycyl-tRNAGly available for translation. Moreover, ribo-
some stalling triggers a secondary translational repression
mechanism, which involves an increase in the phosphoryla-
tion of eIF2 and induction of ISR.
MATERIALS AND METHODS
Cell culture, transfections, and luciferase assay
Human HEK293T cells were grown in Dulbecco’s mod-
ified Eagle’s medium with GlutaMAX™ supplement
(DMEM + GlutaMAX, GIBCO) with 10% FBS. Trans-
fections were done in 10 cm, 6-well and 96-well plates with
polyethylenimine (PEI) using a 1:3 ratio of DNA:PEI. In
reporter experiments, HEK293T cells were transfected with
1–2 ng RL or RL-ATF4, 10 ng FL and 10 ng GARS-myc
constructs per well of a 96-well plate. Total amount of
transfected DNA was topped up to 50 ng per well of
96-well plate with the empty vector. For other formats, the
amounts of plasmids were adjusted proportionally. For myc
immunoprecipitation, amounts of GARS-expressing plas-
mids were adjusted to achieve equal expression levels (1.5
g WT, 3 g E71G and 7.5 g G240R and 10 g ETAQ
GARS-myc per 10 cm plate), and amount of transfected
DNA was topped up to 10 g with the empty vector. Cells
were lysed 24 h post transfection. Luciferase activities
were measured with a homemade luciferase reporter assay
system as described earlier (21). For puromycylation assay,
cells were treated with 2.5 g puromycin for 30 min before
lysis. Where indicated, thapsigargin was added at 50 nM
for 30 min before cell lysis and GCN2-IN-1 at 1 M at the
time of transfection.
Ribosome profiling
Ribosome profiling was performed as earlier described (22),
with the following modifications. Monosomes were purified
using Microspin S-400 HR columns (GE Healthcare 27-
5140-01) and 15–35 nt ribosome-protected fragments were
isolated for library generation.
DNA constructs
Reporter plasmids RL and FL have been described pre-
viously (23). ATF4-RL reporter was generated by PCR
amplifying ATF4 5′UTR (ENSMUST00000109605.5) and
cloning between SacI and NheI of RL. To generate GARS-
myc-expressing plasmid, blasticidin resistance CDS was
PCR amplified and cloned between SbfI and SanDI of pig-
gyBac vector pCyl50-MCS (kind gift of Dr Julien Bethune
(24)), to generate piggyBac-Blast. GARS CDS (P41250-
2) was PCR amplified from human cDNA and cloned
between FseI and AgeI sites of piggyBac-Blast. E71G,
G240R and ETAQ (245-248) mutations were introduced
in GARS CDS by site-directed mutagenesis. To generate
3xflag-NSP1-encoding plasmid, a synthetic 3xflag sequence
was cloned between BstXI and SbfI sites of pEBG-sic plas-
mid (25) to produce pEBG-3xflag. CDS of NSP1 was PCR
amplified, using SARS-CoV2 cDNA as a template, and
cloned between SbfI and NotI sites of pEBG-3xflag.
PAGE and northern blotting
For aminoacylation level experiments, total RNA from
293T cells expressing GARS-myc was isolated with Trizol
(Thermo), according to the manufacturer’s instructions,
and resuspended in 1 mM sodium acetate pH 5.0. A portion
of each sample was subjected to deacylation by addition of
0.2 M Tris–HCl pH 9.5 and incubation at 37◦C for 30 min.
1 g of total RNA per sample was further analyzed by
acid–urea PAGE and northern blotting as described earlier
(26). More specifically, the samples were separated on a 40
cm × 40 cm 10% PAAG (AA:MBA = 19:1) prepared in
0.1 M sodium acetate (pH 5.0) and 8 M urea. The gel was
run at 120 V for 18 h at 4◦C, until the bromophenol blue dye
ran out. For analysis of GARS-myc immunoprecipitates,
samples were run on 10% TBE–urea PAAG at 200 V for
1 h, and 400 ng of total RNA were loaded as inputs.
RNA was then transferred to a Hybond-N + membrane
(Amersham) using semi-dry transfer in 1× TBE buffer
at 15 V for 1 h. The membrane was rinsed in 5× SSC
buffer and RNA was crosslinked to the mebrane using
Stratalinker (265 nm) at 120 000 J/cm2. The membrane
was pre-hybridyzed in 6× SSC, 10× Denhardt solution,
0.5% SDS at 42◦C for 1 h. Hybridization was done in 6×
SSC, 0.1% SDS and 20 pmol of radiolabeled probe at 45◦C
overnight. The membrane was then washed with 2× SSC
three time for 10 min at room temperature and exposed
with the phosphorimager screen for 4 h to overnight.
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(tRNAGly) or oligonucleotide pool (7SK, GFP) was 5′-end
labeled with 10 Ci of  -32P-ATP (3,000 Ci mmol, 10
Ci/l; PerkinElmer) using T4 PNK.
Immunoprecipitation and western blotting
For anti-myc immunoprecipitations (IP), we used 5 g of
anti-myc antibody (AM1007a Abgent) coupled with 50
l of protein G Dynabeads (Thermo) per IP. Antibody-
coupled beads were incubated with 293T cells lysates
overnight at 4◦C. Lysates were prepared from 107 293T cells,
transfected with GARS-myc-expressing constructs, using
lysis buffer (50 mM Tris–HCl pH 7.5, 150 mM NaCl, 0.25%
NP-40, 2 mM Pefabloc). After IP, the beads were washed
three times with the wash buffer (50 mM Tris–HCl pH 7.5,
150 mM NaCl, 0.1% NP-40, 2 mM Pefabloc). 1/20 of the
beads were eluted with the SDS-PAGE sample buffer for
western blotting analysis with anti-myc antibody, with 3%
of inputs and 2.5% of immunoprecipitates loaded on the
gel. The rest of the beads were supplemented with 500 ng
of GFP spike-in RNA, extracted with Trizol according to
the manufacturer’s instructions and isolated RNA was ana-
lyzed by urea PAGE and northern blotting. For GFP RNA
spike-in preparation, a 325-nt fragment of the GFP coding
sequence was PCR amplified with the oligos introducing T7
promoter (T7-GFP-fw: TAATACGACTCACTATAGGG
ATGGTGAGCAAGGGCGAGGA, GFP-rev: GGGTCT
TGTAGTTGCCGTCG), and the resulting PCR fragment
was used as a template for T7 in vitro transcription reaction.
For western blotting, 20 g of total protein, unless oth-
erwise indicated, was separated on a 4–12% SDS-PAGE,
and proteins were transferred to the PVDF membrane. The
membrane was probed with the following primary anti-
bodies: rabbit anti-eIF2a antibody 1:1000 (9722 Cell Sig-
naling), rabbit anti-phospho-eIF2a antibody 1:1000 (9721
Cell Signaling), mouse anti-myc 1:5000 (AM1007a Ab-
gent), mouse anti-beta-actin 1:5000 (A2228 Sigma), mouse
anti-puromycin 1:4000 (Kerafast 3RH11).
Bioinformatical data analysis
Analysis of ribosome profiling data was performed using
an in-house snakemake based pipeline. First, reads were
quality trimmed using trim galore and filtered for common
contaminants (human rRNA sequence (rRNA U13369.1),
tRNA sequences (as predicted by GtRNAdb (27) and se-
lected noncoding RNA sequences from the ENSEMBL
ncrna collection). Filtered reads were then analysed us-
ing fastqc and mapped to the human genome (GRCh38
version97) using STAR (28). Mapped reads were further
analyzed using RiboseQC (https://github.com/ohlerlab/
RiboseQC) to obtain P-site cutoffs and counted using a cus-
tom htseq-based (29) python script split by annotated gene
region, read length and P- and A-site codons. Analysis of
codon usage was performed for CDS-mapping reads with
3 nt periodicity (21 nt and 29 nt). For this, counts for each
codon in A- or P-site were normalized by the sum of all
reads for a given read length, site and sample. Normalized
counts were then summed and averaged between different
conditions.
RESULTS
Defects in protein production are recapitulated by overexpres-
sion of CMT-GARS mutants
CMT2D is caused by the dominant toxic gain-of-function
mutations, i.e. mutations that confer a new and toxic ac-
tivity on GARS protein (3,5,30). This means that the phe-
notype of the disease, including defects in translation, can
be recapitulated by overexpression of mutant GARS. Thus,
we set out to recapitulate the global translational repres-
sion triggered by CMT-GARS mutations E71G, G240R
(7) and deletion of amino acids 245–248 (ETAQ) (31) in
cultured HEK293T cells. For that, we co-transfected cells
with myc-tagged WT or mutant GARS-encoding plasmids
and two reporter constructs coding for Renilla and firefly
luciferase (RL and FL, Figure 1A). An empty vector was
used as a negative control. We found that the overexpres-
sion of E71G, G240R and ETAQ, but not WT GARS, in-
hibited protein production in the luciferase reporter assay
(Figure 1B). Consistently with their role in global transla-
tional downregulation and prior work (7), E71G, G240R
and ETAQ mutant proteins were expressed at lower lev-
els than WT GARS, as revealed by western blotting (Figure
1C). Interestingly, the reporter assay recapitulated the phe-
notypic strength of the mutations observed in in vivo exper-
iments (7,31): the effects of G240R and ETAQ were more
severe than that of E71G (Figure 1B and C).
To analyze the effects of CMT-GARS on total trans-
lation, we used puromycylation assay, which utilizies
puromycin-tagging of newly synthesized proteins (32,33).
Puromycin is a mimic of the aa-tRNA, which is incor-
porated into the nascent polypeptide chains, and the lev-
els of resulting puromycin fusion proteins reflect the rate
of translation. To compare translation levels between the
cells, transfected with either WT or CMT-GARS mu-
tants, we analyzed cell lysate by western blotting with anti-
puromycin antibody (Figure 1D). Indeed, CMT-GARS-
expressing cells showed lower incorporation of puromycin
(anti-puromycin western), in spite of similar protein load-
ing visualized with coomassie staining. These data confirm
that the effect of CMT-GARS mutations on translation is
global.
CMT-GARS mutant inhibits the accommodation of glycyl-
tRNA in the ribosomal A-site and causes ribosome stalling
aa-tRNA synthetases (aaRSs) are required to produce aa-
tRNA for the first step of elongation, i.e. accommodation
of a cognate aminoacyl-tRNA in the ribosomal A-site (Fig-
ure 2A). We decided to test whether this step is affected by
CMT-GARS. Our prediction was that, if glycyl-tRNA were
deficient in CMT-GARS-expressing cells, ribosomes would
stall in a pre-accommodation state once glycine codons
entered their A-site. Recent works have shown that high-
resolution ribosome profiling can distinguish between dif-
ferent functional states of the ribosome––pre- and post-
accommodation of aa-tRNA (20). This technique generates
ribosomal footprints on mRNAs; it is achieved by treat-
ing cell lysates with RNAse I (34). This degrades most
RNA, but leaves ribosome-protected fragments (RPFs)
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Figure 1. Overexpression of CMT-GARS mutants, E71G, G240R and ETAQ, but not WT GARS, represses protein production in cultured cells. (A)
Schematic representation of constructs used in transfection experiments: RL and FL are reporter constructs encoding Renilla and firefly luciferase, corre-
spondingly. Positions of analyzed CMT-GARS mutations in the context of GARS domain structure are shown. (B) Repression of RL and FL mRNAs
by GARS mutants. Human HEK293T cells were co-transfected with plasmids encoding RL, FL, and myc-tagged GARS, either WT or indicated mutant.
As a negative control, empty vector was used instead of GARS-encoding plasmid. RL and FL activities are presented as a percentage of luciferase ac-
tivity produced in the presence of empty vector. Values represent means ± SD from three experiments. (C) Expression levels of myc-fusion proteins were
estimated by western blotting with antibodies directed against myc-tag. Beta-actin was used as a loading control. (D) Puromycylation assay confirms the
role of CMT-GARS in global translational repression. HEK293 cells were transfected with plasmids encoding WT GARS, indicated GARS mutants or
an empty vector. After puromycin treatment, cells were lyzed and lysates were analyzed by western blotting with anti-puromycin antibody. PAAG stained
with coomassie is provided to visualize equal total protein loading between the samples.
sequencing. Due to substantial conformational rearrange-
ments of the ribosome during elongation, ribosomes
lacking tRNA in their A-sites (open A-sites) generate
short 21–22 nt RPFs, while ribosomes with occupied A-
sites––produce long 27–29 nt RPFs (20). Thus, the lack of
a specific aa-tRNA results in ribosomes with open A-sites
pausing on the cognate codons, and this can be detected
by high-resolution ribosome profiling by enrichment of the
corresponding 21–22 nt RPFs (20) (Figure 2A).
To test this hypothesis, we modified the standard ribo-
some profiling protocol (34) to isolate a wide range (15–
35 nt) of RPFs. Triplicate ribosome profiling libraries were
prepared from HEK293T cells expressing a strong CMT-
GARS mutant G240R or WT GARS (negative control).
Most ribosome profiling reads mapped within coding se-
quences (CDS), reflecting a fraction of translated mRNAs,
and showed high correlation between triplicates (Supple-
mentary Figure S1A and B). We observed a bimodal distri-
bution of ribosome footprints, with the peaks correspond-
ing to the ribosomal states with open (21 nt) and occupied
(29 nt) A-sites (Figure 2B). Importantly, both short 21 nt
and long 29 nt RPFs showed a periodic alignment pattern of
3 nt, which reflects the codon-by-codon movement of trans-
lating ribosomes along an mRNA and represents a hall-
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21 nt RPF Accomodation of aa-tRNA
A
Figure 2. Ribosome profiling detects pausing of ribosome with Gly codons in open A-site in G240R-GARS-expressing cells. (A) Scheme showing stages
of elongation and the length of ribosome protected fragments (RPFs) generated by each ribosomal state. aa-tRNA: aminoacyl-tRNA, aaRS: aa-tRNA
synthetase. (B) Length distributions of CDS-mapped ribosome footprints in libraries prepared HEK293T cells expressing either WT or G240R-GARS
(in triplicates). (C) Metagene aggregate plots displaying distance of 21-nt ribosome footprints from annotated start codon. (D) Scatter plots comparing
frequencies of 64 codons in the ribosomal A-site between cells expressing WT (X) and G240R-GARS (Y), for 21 nt (left) and 29 nt (right) RPFs. Ribosome
frequencies represent the means of triplicates. Glycine codons are labelled and marked in red. Insets show differences between codon frequencies in G240R
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We next calculated the mean frequencies of 64 codons
in the A-sites and P-sites of 21 nt and 29 nt RPFs and
compared these values between cells expressing WT and
G240R GARS (Figure 2D and Supplementary Figure
S1D). The most striking difference in codon frequency be-
tween G240R and WT GARS samples was detected for
21 nt RPFs with glycine codons in ribosomal A-site (Fig-
ure 2D, left). We found that ribosomes paused on glycine
codons (red points, Figure 2D) ∼ 2 times longer in G240R
than in WT samples, whereas the values for other codons
remained similar (black points). Notably, such pausing was
observed in short 21 nt RPFs, corresponding to ribosomes
with open A-sites, but not in 29 nt RPFs (<1.3-fold, Fig-
ure 2D, right), representing ribosomes with occupied A-
sites (20). For comparison, only minor changes in codon
frequencies were detected in ribosomal P-sites (<1.5-fold,
Supplementary Figure S1D). Thus, our ribosome profil-
ing data demonstrate that CMT-GARS mutant G240R in-
duces a stalling of ribosomes with glycine codons in open
A-sites, i.e. in a pre-accommodation state. This mechanism
is consistent with a shortage of glycyl-tRNA in G240R-
expressing cells.
CMT-GARS mutants have increased capacity to retain
bound tRNAGly
Stalling of ribosomes with glycine codons in open A-
sites point to a shortage of glycyl-tRNAGly in G240R-
expressing cells. To test if CMT-GARS mutants reduce
levels of aminoacylated tRNAGly, we analyzed the levels
of Gly-tRNAGly in CMT-GARS-expressing 293T cells by
acid–urea polyacrylamide gel electrophoresis (PAGE) fol-
lowed by northern blotting. This method allows separation
of aminoacylated tRNA from deacylated tRNAs due the
mass difference (26). To provide a reference of deacylated
tRNAGly, half of each sample was treated with a basic pH
buffer, that destabilizes an ester bond between the amino
acid carboxyl group and the tRNA terminal 3′-OH group.
This analysis showed that most of analyzed tRNAGly were
aminoacylated in 293T cells, and the aminoacylation levels
were not substantially altered by expression of either WT
or CMT-GARS mutants (Figure 3A). Our results are con-
sistent with the literature data suggesting that CMT-GARS
mutations do not disrupt overall aminocylation activity (3–
5,7).
Toxic gain-of-function phenotypes can result from in-
creased affinity of the interaction with the natural binders,
as observed for example in tauopathies (35). Therefore, we
decided to test if a step downstream of aminoacylation,
such as the release of tRNAGly from GARS, is affected by
CMT-GARS mutations. To this end, we overexpressed WT
GARS and CMT-GARS mutant proteins, tagged with myc-
tag, in 293T cells. Given that CMT-GARS mutants are ex-
pressed at lower levels than WT (Figure 1C), we adjusted the
amounts of transfected plasmids to achieve equal expres-
sion of GARS proteins. We followed with immunoprecipita-
tion of GARS-myc fusion proteins with anti-myc antibod-
ies, in duplicates, and analyzed the levels of bound tRNAGly
by PAGE and northern blotting. To control that the effi-
ciency of RNA recovery was the same between the sam-
ples, we supplemented the immunoprecipitates with in vitro
synthesized GFP RNA spike-in before RNA extraction.
While efficiency of protein immunoprecipitation (Figure
3B, GARS-myc western) and RNA recovery (RNA spike-
in) were similar between the samples, CMT-GARS proteins
retained markedly higher amounts of tRNAGly than WT
GARS (tRNAGly). Thus, our data suggest that, due to slow
release of tRNAGly, CMT-GARS mutants deplete the pool
of glycyl-tRNAGly available for translation.
CMT-GARS induces eIF2a phosphorylation and integrated
stress response
Amino acid starvation and deacylated tRNAs are known to
induce ISR by activating the eIF2a kinase GCN2 (36). Re-
cently, ribosome stalling was reported as an an alternative
mechanism that can activate ISR via the CGN2-mediated
phosphorylation of eIF2a (15,37). Given our evidence for
ribosome stalling in CMT-GARS-expressing cells (Figure
2D), we wondered if this also induced the phosphorylation
of eIF2a and ISR. As a test, we used western blotting to an-
alyze the levels of phosphorylated eIF2a (P-eIF2a) in cells
expressing either mutant or WT GARS (Figure 4A). For a
positive control, we treated HEK293T cells with thapsigar-
gin, a drug that induces the PERK-dependent phosphory-
lation of eIF2a (38). Indeed, we observed that expression
of E71G, G240G and ETAQ mutant GARS increased
the levels of phosphorylated eIF2a, while the total levels of
eIF2a remained unaffected.
eIF2a phosphorylation plays an adaptive role during
stress, by shutting down global protein synthesis, to save
resources, and by upregulating the translation of specific
transcripts, such as ATF4, required for stress management
(10–12). This upregulation occurs through a mechanism in-
volving upstream ORF (uORFs) in ATF4 5′UTR. Under
normal conditions these uORFs play an inhibitory role,
catching scanning ribosomes before they reach the main
ORF. The phosphorylation of eIF2a reduces the amount
of ternary complex, required for initiation, and therefore
increases the chances of scanning ribosomes to reach the
main ORF and initiate translation. To test whether this
mechanism is activated by CMT-GARS mutations, we gen-
erated Renilla luciferase reporter bearing ATF4 5′UTR
(ATF4-RL) and analyzed how CMT-GARS mutants af-
fect its expression (Figure 4B). Renilla reporter without
ATF4 5′UTR (RL) was used as a negative control, and fire-
fly luciferase reporter (FL) was co-transfected with both
Renilla reporters as a normalization control. We observed
that RL and FL reporters were repressed by E71G, G240R
and ETAQ, as established earlier (Figure 1B and Supple-
mentary Figure S2). Strikingly, ATF4-RL was resistant to
CMT-GARS-mediated repression (Supplementary Figure
S2, Figure 4C). Indeed, relative RL/FL expression was up-
regulated by E71G, G240G and ETAQ mutants specifi-
cally for ATF4-RL, but not RL that served as a negative
control (Figure 4C). As a control translational repressor we
used SARS-CoV2 nonstructural protein 1 (NSP1), that in-
hibits global translation initiation by binding and obstruct-
ing the mRNA entry tunnel on the small ribosomal sub-
unit (39,40). Indeed, NSP1 repressed all reporters––ATF4-
RL, RL and FL––to a similar extent (Supplementary Fig-
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(loading control)
Figure 3. CMT-GARS mutants do not impair overall glycylation activity, but have increased capacity to bind tRNAGly. (A) Northern blotting shows
that aminoacylation levels of tRNAGly remain substantially unaffected in the presence of CMT-GARS mutants. HEK293T cells were transfected with
plasmids encoding WT, E71G, G240R, ETAQ GARS or an empty vector, total RNA was isolated and aminoacylation levels of tRNAGly were evaluated
by acid-urea PAGE and northern blotting. Acidic: lanes showing RNA analysed under acidic pH, that preserves ester bonds linking amino acids to tRNAs.
Basic: lanes showing RNA analysed under basic pH, that leads to tRNA deacylation. (B) Immunoprecipitation and northern blotting show that CMT-
GARS mutants have increased capacity to retain bound tRNAGly. HEK293T cells were transfected with plasmids encoding WT, E71G, G240R or ETAQ
GARS-myc, with the amounts of plasmid adjusted to achieve equal protein expression. GARS-myc was immunoprecipitated with anti-myc antibody and
inputs and immunoprecipitates were analyzed by PAGE and northern blotting to evaluate the levels of GARS-myc-bound tRNAGly. To control for equal
efficiency of RNA recovery, immunoprecipitates were supplemented with RNA spike-in before RNA extraction. Duplicates of immunoprecipitates are
shown. Western blotting for inputs and immunoprecipitated GARS-myc is shown as a loading control.
ATF4-RL is specific to GARS mutants. Thus, our data
show that expression of CMT-GARS mutants induces
ATF4 reporter, a marker of ISR.
We next wondered if phosphorylation of eIF2a sub-
stantially contributes to translational repression by CMT-
GARS mutants. To this end, we analyzed how CMT-GARS
proteins affect translation in the presence of the inhibitor
of the eIF2a kinase GCN2, GCN2-IN-1 (41). To evalu-
ate translation levels, we used puromycylation assay intro-
duced in Figure 1D. While addition of GCN2-IN-1 indeed
suppressed eIF2a phosphorylation (Figure 4D, P(Ser51)-
eIF2a), CMT-GARS mutants continued to repress trans-
lation under these conditions (anti-puromycin). Our data
suggest that the primary defect caused by CMT-GARS, i.e.
ribosome pausing on glycine codons, is sufficient to repress
global translation.
DISCUSSION
CMT is the most common inherited neuromuscular disease
affecting 1 in 2500 people worldwide (reviewed in (2)). The
molecular mechanism of CMT has been obscure. Thus, al-
though CMT-causing heterozygous mutations in the glycyl-
tRNA synthetase gene GARS affect protein synthesis, loss
of aminoacylation activity is neither necessary nor sufficient
to cause the disease (3–5,7). Indeed, some of them retain
full (E71G) or partial (G240R) aminoacylation activity, and
the WT allele of GARS produces a fully functional protein
(4,5,7). Moreover, the overexpression of CMT-GARS mu-
tants in Drosophila caused defects in motor performance,
without any reduction in aminoacylation activity and or
changes in the ratios between glycylated versus non gly-
cylated tRNAs (7). Additionally, experiments overexpress-
ing WT GARS did not rescue CMT phenotypes in mouse
or Drosophila models (7,30). These findings suggested that
CMT-GARS mutations inhibit translation via some other
toxic gain-of-function mechanism which remained enig-
matic.
Here, we use high-resolution ribosome profiling to show
directly and for the first time that CMT-GARS mutant
inhibits the first step of elongation – the accommodation
of glycyl-tRNA in the A-site––and thus causes ribosome
stalling (Figures 2D and 5). We propose that the degenera-
tive phenotypes observed in CMT can be attributed to this
stalling. In other cases, ribosome stalling due to deficiencies
in tRNAArg and ribosome rescue factor GTPBP2 in mouse
have been shown to cause neurodegeneration (15).
Our data on ribosome stalling at glycine codons in
open A-site point to an insufficiency of glycyl-tRNAGly in
G240R-expressing cells. However, both our results (Figure
3A) and published data (3–5,7) suggest that CMT-GARS
mutations do not disrupt aminocylation activity. Toxic
gain-of-function mutants can act via different mechanisms,
including increased affinity of the interaction with their nat-
ural binders, acquiring new abnormal binders or a tendency
to aggregate. For example, Alzheimer’s disease-associated
mutants of a microtubule-binding protein tau bind tubu-
lin heterodimers with enhanced affinity (35). Thus, we con-
sidered that a step downstream of aminoacylation, such as
the release of glycyl-tRNAGly from GARS and transfer to
eEF1A:GTP for delivery to ribosome, is likely to be af-
fected by CMT-GARS mutations. Indeed, northern blot-
ting of GARS-CMT immunoprecipitates showed that mu-
tant forms of GARS have increased affinity to tRNAGly
(Figure 3B).
While ribosome stalling explains the mechanism of global
translational repression by CMT-GARS, we show that
it also activates a secondary mechanism of repression at
the level of initiation, by inducing ISR via eIF2a phos-










 Fuer user on 27 Septem
ber 2021











































































































Figure 4. Overexpression of CMT-GARS mutants, E71G, G240R and ETAQ, induces integrated stress response (ISR) via phosphorylation of eIF2a.
(A) Expression of CMT-GARS mutants induces phosphorylation of eIF2a. HEK293T cells were transfected with plasmids encoding WT, E71G, G240R,
ETAQ GARS or an empty vector. For a positive control of eIF2a phosphorylation, cells were treated with thapsigargin. Cell lysates were analyzed by
western blotting using antibodies against phosphorylated eIF2a (P-eIF2a), eIF2a (loading control), and myc (GARS-myc), as indicated on the left. (B)
Schematic representation of reporter constructs used in transfection experiments: RL and FL are the same as in Figure 2A. ATF4-RL carries 5′UTR
of ATF4 gene. (C) E71G, G240R and ETAQ GARS mutants activate expression of ATF4 reporters. Human HEK293T cells were co-transfected with
plasmids encoding one of the Renilla luciferase reporters (RL, ATF4-RL), FL and myc-tagged GARS, either WT or indicated mutant. As additional
controls, empty vector and NSP1-encoding plasmids were used instead of GARS plasmid. RL activity was normalized to that of FL and presented as a
percentage of luciferase activity produced in the presence of empty vector for each Renilla reporter. Values represent means ± SD from three experiments.
(D) Puromycylation assay shows that CMT-GARS-mediated translational repression is preserved upon inhibition of eIF2a phosphorylation. HEK293T
cells were transfected with plasmids encoding WT, E71G, G240R or ETAQ GARS and inhibitor of eIF2a phosphorylation phosphorylation GCN2-IN-1
was added were indicated. After puromycin treatment, cells were lyzed and lysates were analyzed by western blotting with antibodies against phosphorylated
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Figure 5. Model illustrating the mechanism of CMT-mutant GARS function in translational regulation. CMT-mutant GARS protein inhibits accommo-
dation of glycyl-tRNA into the ribosomal A-site, possibly via decreasing the pool of available charged glycyl-tRNA, and leads to ribosome stalling on
glycine codons. Ribosome stalling results in phosphorylation of eIF2a and activation of integrated stress response. In particular, phosphorylation of eIF2a
leads to reduction in the levels of ternary complex eIF2:GTP:Met-tRNAi, which downregulates global translation initiation and upregulates expression of
selected transcripts with uORFs, such as ATF4. When levels of ternary complex are low, ribosomes bypass uORF, which allows them to initiate translation
on the main ATF4 ORF. ATF4 is a transcription factor that induces stress response genes.
ribosomes are more potent activators of the eIF2a kinase
GCN2 than deacylated tRNAs, which result from amino
acid starvation (15,37). Interaction with ribosomal P-stalk
of stalled ribosomes is suggested to activate GCN2 (37),
although the exact mechanism of discrimination between
translating and stalled ribosomes remains unclear. The
phosphorylation of eIF2a prevents the formation of the
ternary complex and thus inhibits global translation initi-
ation, to save cellular resources (Figure 5). Beyond that, it
enhances the translation of specific mRNAs, such as ATF4,
which contains uORFs in it 5′UTRs (10–12). ATF4 pro-
motes the transcription of genes with adaptive functions
that can repair damage caused by stress (42,43). However,
a chronic activation of ISR can contribute to neurode-
generative phenotypes through the induction of apoptosis,
memory impairments due to translational inhibition and
other mechanisms (reviewed in (1)). For example, ATF4 de-
ficiency was shown to alleviate neuronal loss from oxidative
stress and amyloid beta peptide (44,45).
It remains unclear why mutations in ubiquitously ex-
pressed aaRSs primarily affect peripheral motor and sen-
sory axons. The fact that the expression of CMT-GARS
mutants in a heterologous system permits recapitulating the
repression of protein production, characteristic of CMT
(Figure 1B), suggests that the mechanism per se is not
unique to a single cell type. One possible explanation for the
higher susceptibility of peripheral motor and sensory axons
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components that are involved in this mechanism (e.g. tR-
NAs, aaRSs etc.). Further studies aimed at identifying such
limiting components are likely to elucidate the cell speci-
ficity of this mechanism.
There is no cure for CMT and understanding of the
mechanisms of the CMT-GARS function opens new per-
spectives for development of therapies. Antisense oligos
(ASO) are a promising therapeutic strategy to downregu-
late genes with toxic gain-of-function phenotype (reviewed
in (46)). ASO injections produced encouraging results in
treatment of several neurological diseases, including spinal
muscular atrophy and Huntington’s disease. In case of CMT
however, this approach would require generation of indi-
vidualized ASOs recognizing specific CMT-GARS muta-
tions, which in most cases differ from a WT allele in a sin-
gle nucleotide, making the ASO design complicated. An al-
ternative approach to therapies is targeting different steps
of the CMT-GARS-mediated translational repression. Our
data on ribosome stalling at glycine codons in open A-site
point to the shortage of glycyl-tRNA as a mechanism of
CMT. Therefore, providing a supply tRNAGly could be a
therapeutic strategy to alleviate ribosome pausing. Activa-
tion of ISR may also contribute to neurodegenerative phe-
notypes in CMT, supported by data from other neurode-
generative diseases (reviewed in (1)). Indeed, drugs target-
ing ISR and alleviating translational repression have been
shown to efficiently reduce neurodegeneration symptoms in
various models (13) and may be a promising approach for
treatment of CMT.
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